出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/08/19 14:53:07」(JST)[Wiki en表示]
- Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.
- Figus M1, Nardi M1, Piaggi P2, Sartini M1, Guidi G1, Martini L1, Lazzeri S1.Author information 1Ophthalmology Unit, Department of Surgical, Medical and Molecular Pathology, and Critical Area, University of Pisa, Pisa, Italy.2Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy.AbstractPurposeTo evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and 0.01% ophthalmic solutions.MethodsThis was a randomized, prospective, parallel-group, open-label, cohort study. A total of 60 glaucoma patients (60 eyes) under bimatoprost 0.03% monotherapy since at least 1 year were enrolled. Selected patients were randomized to receive a single drop of bimatoprost 0.01% (n=30) or bimatoprost 0.03% (n=30) ophthalmic solutions for 12 months. Statistical analysis was performed using paired t-test and repeated measures ANOVA test.ResultsGlobal clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7±3.8 to 2.9±2.3 (P<0.001) and 2.5±2.0 (P<0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P=0.003 and P<0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (P<0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (P<0.05) and in comparison with bimatoprost 0.03% (P<0.05).ConclusionThe results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.Eye advance online publication, 17 January 2014; doi:10.1038/eye.2013.304.
- Eye (London, England).Eye (Lond).2014 Jan 17. doi: 10.1038/eye.2013.304. [Epub ahead of print]
- PurposeTo evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and 0.01% ophthalmic solutions.MethodsThis was a randomized, prospective, parallel-group, open-label, cohort study. A total of 60 glaucoma patients (60 eyes) under bimatoprost 0.03% monotherapy si
- PMID 24434659
- Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: An Adjusted Indirect Comparison Meta-Analysis of Randomized Clinical Trials.
- Cucherat M, Stalmans I, Rouland JF.Author information *UMR CNRS 5558, Faculté de Médecine Laennec, Lyon ‡Ophthalmology Department, University of Lille, Lille, France †Ophthalmology Department, University Hospitals Leuven, Leuven, Belgium.AbstractAIM: : To assess the relative efficacy and tolerability of preservative-free latanoprost (T2345) compared with other prostaglandin analogues (PGA) for the treatment of open-angle glaucoma and ocular hypertension by adjusted indirect comparison meta-analysis.
- Journal of glaucoma.J Glaucoma.2014 Jan;23(1):e69-75. doi: 10.1097/IJG.0b013e3182a075e6.
- AIM: : To assess the relative efficacy and tolerability of preservative-free latanoprost (T2345) compared with other prostaglandin analogues (PGA) for the treatment of open-angle glaucoma and ocular hypertension by adjusted indirect comparison meta-analysis.METHODS: Randomized, controlled trials eva
- PMID 23881267
- Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
- Ahluwalia GS.Author information Clinical Dermatology R&D, Clinical Development, Allergan, Irvine, California, USA.AbstractFew dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of eyelash hypotrichosis. The product was investigated in a double-masked, randomized, and placebo-controlled study in patients who had significant eyelash loss or hypotrichosis as a result of chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.
- The journal of investigative dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. [and] European Society for Dermatological Research.J Investig Dermatol Symp Proc.2013 Dec;16(1):S73-6. doi: 10.1038/jidsymp.2013.30.
- Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription pr
- PMID 24326568
- 正常眼圧緑内障に対するトラボプロスト,タフルプロスト,ビマトプロストの眼圧下降効果の検討 (第22回日本緑内障学会)
- 田邉 祐資,菅野 誠,山下 英俊
- あたらしい眼科 29(8), 1131-1135, 2012-08
- NAID 40019415652
- 広田 篤,井上 康,永山 幹夫,相良 健,岡田 康志,古本 淳士,木内 良明
- あたらしい眼科 = Journal of the eye 29(2), 259-265, 2012-02-29
- NAID 10030234844
- Bimatoprost (marketed in the U.S., Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular ...
- 29 Oct 2012 ... If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair ...